Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine J Sadoff, M Le Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... New England Journal of Medicine 384 (19), 1824-1835, 2021 | 1276 | 2021 |
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys DH Barouch, JB Whitney, B Moldt, F Klein, TY Oliveira, J Liu, ... Nature 503 (7475), 224-228, 2013 | 816 | 2013 |
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys P Abbink, RA Larocca, RA De La Barrera, CA Bricault, ET Moseley, ... Science 353 (6304), 1129-1132, 2016 | 575 | 2016 |
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys DH Barouch, KE Stephenson, EN Borducchi, K Smith, K Stanley, ... Cell 155 (3), 531-539, 2013 | 375 | 2013 |
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) DH Barouch, FL Tomaka, F Wegmann, DJ Stieh, G Alter, ML Robb, ... The Lancet 392 (10143), 232-243, 2018 | 350 | 2018 |
Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans G Alter, J Yu, J Liu, A Chandrashekar, EN Borducchi, LH Tostanoski, ... Nature 596 (7871), 268-272, 2021 | 347 | 2021 |
Immunogenicity of the Ad26. COV2. S Vaccine for COVID-19 KE Stephenson, M Le Gars, J Sadoff, AM de Groot, D Heerwegh, ... Jama 325 (15), 1535-1544, 2021 | 341 | 2021 |
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys EN Borducchi, C Cabral, KE Stephenson, J Liu, P Abbink, D Ng’ang’a, ... Nature 540 (7632), 284-287, 2016 | 299 | 2016 |
Durable humoral and cellular immune responses 8 months after Ad26. COV2. S vaccination DH Barouch, KE Stephenson, J Sadoff, J Yu, A Chang, M Gebre, ... New England Journal of Medicine 385 (10), 951-953, 2021 | 255 | 2021 |
Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques M Aid, K Busman-Sahay, SJ Vidal, Z Maliga, S Bondoc, C Starke, M Terry, ... Cell 183 (5), 1354-1366. e13, 2020 | 221 | 2020 |
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo … K Modjarrad, L Lin, SL George, KE Stephenson, KH Eckels, ... The Lancet 391 (10120), 563-571, 2018 | 213 | 2018 |
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting B Julg, L Dee, J Ananworanich, DH Barouch, K Bar, M Caskey, DJ Colby, ... The lancet HIV 6 (4), e259-e268, 2019 | 182 | 2019 |
HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design CA Bricault, K Yusim, MS Seaman, H Yoon, J Theiler, EE Giorgi, K Wagh, ... Cell host & microbe 25 (1), 59-72. e8, 2019 | 160 | 2019 |
Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019 RM Burwick, S Yawetz, KE Stephenson, ARY Collier, P Sen, ... Clinical Infectious Diseases 73 (11), e3996-e4004, 2021 | 158 | 2021 |
Zika virus vaccines P Abbink, KE Stephenson, DH Barouch Nature Reviews Microbiology 16 (10), 594-600, 2018 | 142 | 2018 |
Chikungunya fever K Bartholomeeusen, M Daniel, DA LaBeaud, P Gasque, RW Peeling, ... Nature Reviews Disease Primers 9 (1), 17, 2023 | 115 | 2023 |
Broadly neutralizing antibodies for HIV eradication KE Stephenson, DH Barouch Current Hiv/aids Reports 13, 31-37, 2016 | 114 | 2016 |
Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 113 | 2022 |
Safety and immunogenicity of the Ad26. COV2. S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial J Sadoff, ML Gars, G Shukarev, D Heerwegh, C Truyers, AM de Groot, ... MedRxiv, 2020.09. 23.20199604, 2020 | 113 | 2020 |
Vaccines and broadly neutralizing antibodies for HIV-1 prevention KE Stephenson, K Wagh, B Korber, DH Barouch Annual review of immunology 38 (1), 673-703, 2020 | 102 | 2020 |